8-K filed Aug 4, 2026 at 16:09 ET
Ultragenyx reported Q2 2026 revenue of $214M (beat $183.1M consensus by 17%, +28% YoY) and EPS of -$0.90 (beat -$1.00 consensus by 10%, narrowed from -$1.17 YoY). All products showed strong growth, full-year 2026 guidance was reaffirmed, and management reiterated its path to profitability in 2027. The company highlighted upcoming H2 catalysts: two PDUFA dates (DTX401 gene therapy Aug 23, UX111 gene therapy Sep 19) and GTX-102 Phase 3 Angelman data in Sep/Oct.